Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: Efficacy and toxicity of a low cumulative radiation dose schedule

Gynecologic Oncology

Volumn 126, Issue 2, 2012, Pages 211-216

  Toita, Takafumi ^a   Kitagawa, Ryo ^b   Hamano, Tetsutaro ^c   Umayahara, Kenji ^d   Hirashima, Yasuyuki ^e   Aoki, Yoichi ^a   Oguchi, Masahiko ^d   Mikami, Mikio ^f   Takizawa, Ken ^d  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b Nippon Telegraph and Telephone Corporation Medical Center Tokyo   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

^f TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cervix cancer; Chemotherapy; Radiotherapy

Indexed keywords

CISPLATIN;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER SIZE; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; COLITIS; CYSTITIS; ENTERITIS; FEMALE; FOLLOW UP; HUMAN; INCONTINENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PELVIS PAIN SYNDROME; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROCTITIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING; URETER OBSTRUCTION; URINE RETENTION; UTERINE CERVIX CANCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 84862891477     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.04.036     Document Type: Article

References (32)

1. Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol 2007;25:2952-65. (Pubitemid 47123160)
2. Toita T, Kodaira T, Shinoda A, et al. Patterns of radiotherapy practice for patients with cervical cancer (1999-2001): patterns of care study in Japan. Int J Radiat Oncol Biol Phys 2008;70:788-94.
3. Viswanathan AN, Creutzberg CL, Craighead P, et al. International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys 2012;82:250-5.
4. Stewart AJ, Viswanathan AN. Current controversies in high-dose-rate versus low-dose- rate brachytherapy for cervical cancer. Cancer 2006;107:908-15. (Pubitemid 44291138)
5. Toita T, Moromizato H, Ogawa K, et al. Concurrent chemoradiotherapy using high-dose- rate intracavitary brachytherapy for uterine cervical cancer. Gynecol Oncol 2005;96:665-70. (Pubitemid 40255485)
6. Novetsky AP, Einstein MH, Goldberg GL, et al. Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two high-dose-rate brachytherapy insertions for the treatment of locally advanced cervical cancer. Gynecol Oncol 2007;105:635-40. (Pubitemid 46734184)
7. Ozsaran Z, Kamer S, Yalman D, et al. Treatment results and prognostic factors for cervical cancer patients treated by radiochemotherapy with weekly cisplatin. Eur J Gynaecol Oncol 2007;28:196-200. (Pubitemid 46985641)
8. Parker K, Gallop-Evans E, Hanna L, et al. Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution. Int J Radiat Oncol Biol Phys 2009;74:140-6.
9. Chen SW, Liang JA, Hung YC, et al. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications. Int J Radiat Oncol Biol Phys 2006;66:1370-7.
10. Lim A, Sia S. Outcomes of chemoradiotherapy in cervical cancer-the Western Australian experience. Int J Radiat Oncol Biol Phys 2012;82:1431-8.
11. Anker CJ, Cachoeira CV, Boucher KM, et al. Does the entire uterus need to be treated in cancer of the cervix? Role of adaptive brachytherapy. Int J Radiat Oncol Biol Phys 2010;76:704-12.
12. Forrest JL, Ackerman I, Barbera L, et al. Patient outcome study of concurrent chemoradiation, external beam radiotherapy, and high-dose rate brachytherapy in locally advanced carcinoma of the cervix. Int J Gynecol Cancer 2010;20:1074-8.
13. Souhami L, Seymour R, Roman TN, et al. Weekly cisplatin plus external beam radiotherapy and high dose rate brachytherapy in patients with locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1993;27:871-8. (Pubitemid 23340299)
14. Lanciano R, Calkins A, Bundy BN, et al. Randomized comparison ofweekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol 2005;23:8289-95.
15. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008;108:317-25.
16. DiSilvestro PA, Walker JL, Morrison A, et al. Gynecologic Oncology Group. Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group. Gynecol Oncol 2006;103:1038-42. (Pubitemid 44821331)
17. Walker JL, Morrison A, DiSilvestro P, et al. Gynecologic Oncology Group. A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study. Gynecol Oncol 2009;112:78-84.
18. Gaffney DK, Winter K, Dicker AP, et al. A phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128. Int J Radiat Oncol Biol Phys 2007;67:104-9. (Pubitemid 44959486)
19. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008;26:5802-12.
20. Vale C, Nightingale A, Spera N, et al. Late complications from chemoradiotherapy for cervical cancer: reflections from cervical cancer survivors 10 years after the national cancer institute alert. Clin Oncol (R Coll Radiol) 2010;22:588-9.
21. Viswanathan AN, Dimopoulos J, Kirisits C, Berger D, Pötter R. Computed tomography versus magnetic resonance imaging-based contouring in cervical cancer brachytherapy: results of a prospective trial and preliminary guidelines for standardized contours. Int J Radiat Oncol Biol Phys 2007;68:491-8. (Pubitemid 46694166)
22. Toita T, Kakinohana Y, Ogawa K, et al. Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule. Int J Radiat Oncol Biol Phys 2003;56:1344-53. (Pubitemid 36842886)
23. Nakano T, Kato S, Ohno T, et al. Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer 2005;103:92-101. (Pubitemid 39665461)
24. Pötter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006;78:67-77. (Pubitemid 43131038)
25. Tod M, Meredith W. A dosage system for use in the treatment of cancer of the uterine cervix. Br J Radiol 1938;11:809-24.
26. International Commission on Radiation Units and Measurements. Dose and volume specification for reporting intracavitary therapy in gynecology. ICRU report 38. Washington: ICRU; 1985. p. 11-2.
27. Toita T, Kato S, Ishikura S, et al. Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer. Int J Clin Oncol 2011;16:379-86.
28. Coia L, Won M, Lanciano R, et al. The Patterns of Care Outcome Study for cancer of the uterine cervix. Results of the Second National Practice Survey. Cancer 1990;66:2451-6.
29. The 38th annual report of gynecologic tumors committee. Acta Obstet Gynaecol Jpn 2004;56:751-65.
30. Viswanathan AN, Erickson BA. Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 2010;76:104-9.
31. Dimopoulos JC, Pötter R, Lang S, et al. Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy. Radiother Oncol 2009;93:311-5.
32. Narayan K, van Dyk S, Bernshaw D, et al. Comparative study of LDR (Manchester system) and HDR image-guided conformal brachytherapy of cervical cancer: patterns of failure, late complications, and survival. Int J Radiat Oncol Biol Phys 2009;74:1529-35.